Skip to main content
Premium Trial:

Request an Annual Quote

Good Start Genetics Raises $14M in Series B Financing

NEW YORK (GenomeWeb News) – Good Start Genetics today announced the initial closing of a Series B Preferred Stock financing that raised $14 million.

The funds will be used to support commercialization efforts of the Cambridge, Mass.-based firm's screening tests and to support R&D work to develop its proprietary platform technology for future applications, it said.

Existing investors OrbiMed Advisors, Safeguard Scientifics, and SV Life Sciences led the financing round.

Good Start is using next-generation sequencing technology to develop tests for all American Congress of Obstetricians and Gynecologists and American College of Medical Genetics and Genomics recommended disorders, it said. The company raised $18 million in a Series A round in 2010.

The firm today also announced several new hires and promotions. The new hires include Jean Franchi as CFO. He was previously at Genyzme, where he held several senior business positions, including senior vice president of corporate finance.

The firm also hired Paul Ethridge as VP of human resources and Laura Sullivan as VP of customer care and reimbursement.

Gregory Porreca, a founder of Good Start, was promoted to VP of R&D. He co-developed with Danaher Motion Dover the Polonator high-throughput DNA sequencer, and co-developed a next-gen sequencing platform that Applied Biosystems, now part of Life Technologies, eventually developed into the SOLiD system.

Additionally, Stephanie Hallam was promoted to VP of laboratory operations and medical director. She previously was VP of operations and quality systems at Allegro Diagnostics, director of clinical operations at Genzyme Genetics, and laboratory director at Athena Diagnostics, Kimball Genetics, and the University of Utah.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.